Browse by author
Lookup NU author(s): Professor Andrew GenneryORCiD, Professor Mary Slatter, Professor Andrew Cant
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2014 American Academy of Allergy, Asthma & Immunology. Background Common variable immunodeficiency (CVID) is usually well controlled with immunoglobulin substitution and immunomodulatory drugs. A subgroup of patients has a complicated disease course with high mortality. For these patients, investigation of more invasive, potentially curative treatments, such as allogeneic hematopoietic stem cell transplantation (HSCT), is warranted. Objective We sought to define the outcomes of HSCT for patients with CVID. Methods Retrospective data were collected from 14 centers worldwide on patients with CVID receiving HSCT between 1993 and 2012. Results Twenty-five patients with CVID, which was defined according to international criteria, aged 8 to 50 years at the time of transplantation were included in the study. The indication for HSCT was immunologic dysregulation in the majority of patients. The overall survival rate was 48%, and the survival rate for patients undergoing transplantation for lymphoma was 83%. The major causes of death were treatment-refractory graft-versus-host disease accompanied by poor immune reconstitution and infectious complications. Immunoglobulin substitution was stopped in 50% of surviving patients. In 92% of surviving patients, the condition constituting the indication for HSCT resolved. Conclusion This multicenter study demonstrated that HSCT in patients with CVID was beneficial in most surviving patients; however, there was a high mortality associated with the procedure. Therefore this therapeutic approach should only be considered in carefully selected patients in whom there has been extensive characterization of the immunologic and/or genetic defect underlying the CVID diagnosis. Criteria for patient selection, refinement of the transplantation protocol, and timing are needed for an improved outcome.
Author(s): Wehr C, Gennery AR, Lindemans C, Schulz A, Hoenig M, Marks R, Recher M, Gruhn B, Holbro A, Heijnen I, Meyer D, Grigoleit G, Einsele H, Baumann U, Witte T, Sykora K-W, Goldacker S, Regairaz L, Aksoylar S, Ardeniz O, Zecca M, Zdziarski P, Meyts I, Matthes-Martin S, Imai K, Kamae C, Fielding A, Seneviratne S, Mahlaoui N, Slatter MA, Gungor T, Arkwright PD, Van Montfrans J, Sullivan KE, Grimbacher B, Cant A, Peter H-H, Finke J, Gaspar HB, Warnatz K, Rizzi M
Publication type: Article
Publication status: Published
Journal: Journal of Allergy and Clinical Immunology
Year: 2015
Volume: 135
Issue: 4
Pages: 988-997.e6
Print publication date: 01/04/2015
Online publication date: 14/01/2015
Acceptance date: 19/11/2014
ISSN (print): 0091-6749
ISSN (electronic): 1097-6825
Publisher: Mosby Inc.
URL: https://doi.org/10.1016/j.jaci.2014.11.029
DOI: 10.1016/j.jaci.2014.11.029
PubMed id: 25595268
Altmetrics provided by Altmetric
